Demographic and treatment characteristics of patients
| . | BMT . | PBSCT . | P . |
|---|---|---|---|
| No. patients | 54 | 37 | |
| Median age (range), y | |||
| Patients | 40 (18-56) | 40 (17-58) | NS |
| Donors | 37 (23-55) | 34 (20-52) | NS |
| Sex, no. (%) | |||
| Male, with male donor | 27 (50) | 19 (51) | NS |
| Male, with female donor | 8 (15) | 3 (8) | NS |
| Female, with female donor | 15 (28) | 11 (30) | NS |
| Female, with male donor | 4 (7) | 4 (11) | NS |
| Median time from diagnosis to transplantation (range), mo. | 24 (4-86) | 16 (3-71) | .05 |
| Median graft size (range) | |||
| Nucleated cell dose (× 108/kg) | 3.11 (1.58-5.02) | 13.8 (4.35-29.61) | .001 |
| CD34+ cell dose (× 106/kg) | 3.35 (1.5-6.83) | 8.40 (4.2-42.8) | .001 |
| GVHD prophylaxis, no. | |||
| Methotrexate and cyclosporine A | 54 | 37 | |
| Without day 11 methotrexate | 3 | 0 | NS |
| Myeloablative regimen, no. (%) | |||
| TBI and cyclophosphamide | 52 (96) | 35 (94) | NS |
| Busulfan and cyclophosphamide | 2 (4) | 1 (3) | NS |
| TBI and fludarabine | — | 1 (3) | |
| Cytomegalovirus status, no. (%) | |||
| Seropositive, seropositive donor | 14 (26) | 7 (19) | NS |
| Seropositive, seronegative donor | 11 (20) | 10 (27) | NS |
| Seronegative, seronegative donor | 26 (48) | 20 (54) | NS |
| Seronegative, seropositive donor | 3 (6) | 0 (0) | NS |
| Patients receiving G-CSF, no. (%) | 4 (7) | 2 (5) | NS |
| Median follow-up (range), mo. | 29 (2-68) | 17 (2-41) | .01 |
| . | BMT . | PBSCT . | P . |
|---|---|---|---|
| No. patients | 54 | 37 | |
| Median age (range), y | |||
| Patients | 40 (18-56) | 40 (17-58) | NS |
| Donors | 37 (23-55) | 34 (20-52) | NS |
| Sex, no. (%) | |||
| Male, with male donor | 27 (50) | 19 (51) | NS |
| Male, with female donor | 8 (15) | 3 (8) | NS |
| Female, with female donor | 15 (28) | 11 (30) | NS |
| Female, with male donor | 4 (7) | 4 (11) | NS |
| Median time from diagnosis to transplantation (range), mo. | 24 (4-86) | 16 (3-71) | .05 |
| Median graft size (range) | |||
| Nucleated cell dose (× 108/kg) | 3.11 (1.58-5.02) | 13.8 (4.35-29.61) | .001 |
| CD34+ cell dose (× 106/kg) | 3.35 (1.5-6.83) | 8.40 (4.2-42.8) | .001 |
| GVHD prophylaxis, no. | |||
| Methotrexate and cyclosporine A | 54 | 37 | |
| Without day 11 methotrexate | 3 | 0 | NS |
| Myeloablative regimen, no. (%) | |||
| TBI and cyclophosphamide | 52 (96) | 35 (94) | NS |
| Busulfan and cyclophosphamide | 2 (4) | 1 (3) | NS |
| TBI and fludarabine | — | 1 (3) | |
| Cytomegalovirus status, no. (%) | |||
| Seropositive, seropositive donor | 14 (26) | 7 (19) | NS |
| Seropositive, seronegative donor | 11 (20) | 10 (27) | NS |
| Seronegative, seronegative donor | 26 (48) | 20 (54) | NS |
| Seronegative, seropositive donor | 3 (6) | 0 (0) | NS |
| Patients receiving G-CSF, no. (%) | 4 (7) | 2 (5) | NS |
| Median follow-up (range), mo. | 29 (2-68) | 17 (2-41) | .01 |
BMT indicates bone marrow transplantation; PBSCT, peripheral blood stem cell transplantation; GVHD, graft-versus-host disease; TBI, total body irradiation; G-CSF, granulocyte colony-stimulating factor.